CPT-11 (Irinotecan) in the treatment of colorectal cancer

J. P. Armand, M. Ducreux, M. Mahjoubi, D. Abigerges, R. Bugat, G. Chabot, P. Herait, M. de Forni, P. Rougier

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    116 Citations (Scopus)

    Résumé

    Colorectal cancer is one of the most common cancers in the Western World. Although 50% of patients are cured by surgery alone, the outcome is poor in high-risk patients (Dukes stages B2 and C) despite adjuvant chemotherapy with 5-fluorouracil (5-FU)-based regimens. CPT-11 (irinotecan) is a promising new agent for the treatment of colorectal cancer with a unique mechanism of action. CPT-11 is a DNA topoisomerase I inhibitor, which has not demonstrated susceptibility to the P-glycoprotein-mediated multidrug-resistant phenotype. Phase II studies with CPT-11 have demonstrated definite activity against colorectal cancer in both chemotherapy-naive and pretreated patients (response rates of 15-32% observed) even with clinical evidence of resistance to 5-FU. The response rate appears to be consistent, reproducible and equivalent to that achieved with 5-FU plus folinic acid in chemotherapy-naive patients.

    langue originaleAnglais
    Pages (de - à)1283-1287
    Nombre de pages5
    journalEuropean Journal of Cancer
    Volume31
    Numéro de publication7-8
    Les DOIs
    étatPublié - 1 janv. 1995

    Contient cette citation